Medicines360 Announces Price Subsidy of its Hormonal IUD Avibela to Expand Access to Contraception

In August 2021 – Medicines360, the mission-driven nonprofit Women’s Health pharmaceutical organization announced a price subsidy to expand contraceptive access for millions of women in some of the world’s poorest countries. When purchased from its subsidiary, Impact RH360, Avibela will be offered at the price of $9.50 through international procurement groups.

“We believe that women everywhere should have the right to choose from a broad mix of safe, effective, and affordable contraceptive methods,” said Chief Executive Officer Tina Raine-Bennett, MD, MPH. “As a purpose-driven organization, we are excited to be able to expand contraceptive access by offering a subsidized price for Avibela via international procurement group catalogs through 2024. Creating a price that works for the public sector reflects our ongoing efforts and those of our valued partners and customers to expand the availability of Avibela to the global community.”

The Guttmacher Institute estimates that over 218 million women[1] in low- and middle-income countries have an unmet need for contraception. According to the Guttmacher Institute, the health implications of such a large unmet need are profound. Every year, an estimated 74 million unintended pregnancies occur in developing regions, the great majority of which are among women using no contraception or a traditional method. Fully addressing all unmet needs could prevent the deaths of 70,000 women from pregnancy-related causes[2].

The levonorgestrel-releasing intrauterine device (hormonal IUD) is one of the most effective forms of contraception and offers important non-contraceptive health benefits. Historically however, it has not been widely available in developing countries, largely due to the high price of existing products; pushing it out of women’s financial reach. This subsidy aims to bring greater choice and access to millions of women in some of the world’s poorest regions.

The Avibela Project® was first launched to expand access to hormonal IUDs in developing countries. Through its subsidiary Impact RH360, Medicines360 makes its hormonal IUD available to NGOs and works together with them to support registration, provider training, and product launch. Impact RH360 is a wholly owned, non-profit subsidiary formed to focus on maximizing impact in low- and middle-income countries. Medicines360 is a member of the Hormonal IUD Access Group, a consortium made up of donors, researchers, service delivery organizations, and product suppliers with the goal of sharing learnings to facilitate the introduction of the hormonal IUD across the globe.

About Medicines360

Headquartered in San Francisco, CA Medicines360 is the first “nonprofit pharma” entity focused on Women’s Health in the U.S. and globally. Combining the rigor and expertise of a commercial pharmaceutical company with the pro-social ambitions of a nonprofit, Medicines360’s mission is to catalyze equitable access to medicines and devices for women everywhere. For more information, visit www.medicines360.org.


[1] https://www.guttmacher.org/report/adding-it-up-investing-in-sexual-reproductive-health-2019

[2] https://www.guttmacher.org/report/unmet-need-for-contraception-in-developing-countries

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org.

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.